Skip to main content

Table 1 PSQI total and individual scores throughout the study period

From: Trazodone for the treatment of fibromyalgia: an open-label, 12-week study

  baseline week 6 week 12 P (anova)
Total score (mean ± s.d.) 16.2 ± 3.3 12.9 ± 4.1*** 12.1 ± 5.0*** < 0.0001
ES   1.00 1.24  
Sleep quality (mean ± s.d.) 3.58 ± 0.5 1.78 ± 0.9*** 1.64 ± 0.9*** < 0.0001
ES   3.6 3.88  
Sleep latency (mean ± s.d.) 2.49 ± 0.8 2.2 ± 0.9** 1.9 ± 1.1*** < 0.0001
ES   0.36 0.73  
Sleep duration (mean ± s.d.) 2.58 ± 0.6 1.98 ± 1.0*** 1.75 ± 1.1*** < 0.0001
ES   1.00 1.38  
Sleep efficiency (mean ± s.d.) 2.68 ± 0.7 2.03 ± 1.2*** 1.59 ± 2.2*** < 0.0001
ES   0.93 1.56  
Sleep disturbance (mean ± s.d.) 2.36 ± 0.5 2.07 ± 0.6** 2.02 ± 0.7*** = 0.0001
ES   0.58 0.68  
Sleeping medications (mean ± s.d.) 1.42 ± 1.5 0.97 ± 1.4* 0.73 ± 1.2** = 0.0033
ES   0.30 0.46  
Daytime dysfunction (mean ± s.d.) 2.32 ± 0.8 2.02 ± 0.9** 1.98 ± 0.9** = 0.0013
ES   0.38 0.42  
  1. *: p < 0.05, **:p < 0.01, and ***: p < 0.001 in relation to baseline (Dunnett's post-test)
  2. ES: effect size; bold: moderate and large effect sizes